Clinical trial
Modulation of Executive Functions and Speech in Parkinson's Disease by Theta tACS Targeted at the Medial Frontal Cortex
NCT07240272 is registered in ClinicalTrials.gov with Ke Dong, MD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Modulation of Executive Functions and Speech in Parkinson's Disease by Theta tACS Targeted at the Medial Frontal Cortex
- Lead sponsor
- Ke Dong, MD
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- August 1, 2023
- Completion date
- August 1, 2025
- Enrollment
- 28 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.